Monoclonal antibody (mAb) treatment has revolutionized the approach to many diseases and represents a fast-growing area of drug development. 1, 2 They are composed of immunoglobulin G (IgG) isotypes, divided into four subclasses. 3 In 1986, the US Food and Drug Administration (FDA) approved muromonab-CD3, the first mouse-derived therapeutic mAb indicated for transplant rejection. 4 Human or "fully human" mAbs were later developed in 2002 that contained human heavy and light chains.
days per month) or chronic migraine (≥15 headache days per month).
LY2951742 is a humanized mAb targeted against the CGRP ligand (CGRP itself). In a phase II study of patients with episodic migraines, subcutaneous (SC) administration of LY2951742 (150 mg every 2 weeks) resulted in a reduction from baseline at week 12 of 1.2 days compared with placebo. 13 In a separate phase II study, ALD403, another humanized mAb against the CGRP ligand, showed similar results at weeks 5 to 8; intravenous (IV) administration of ALD403 (1,000 mg) reduced monthly migraine headaches by 1.0 day compared with the placebo group. 14 
